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Introduction
Joint bleeds cause major morbidity in hemophilia [1] , but also occur after trauma [2] and major joint surgery [3] , or as a complication of anticoagulant treatment [4] . Although even a single bleed can lead to significant joint damage, in particular, repeated joint bleeds are devastating for cartilage, synovium and bone [5] [6] [7] [8] . In hemophilia, replacing the missing clotting factor aims to limit these joint bleeds, but cannot fully prevent them [9] . Once arthropathy is present, conservative management is indicated to alleviate symptoms [10, 11] and to postpone orthopedic interventions, which are often necessary in advanced stages [12] . Disease controlling agents, such as those proven effective in rheumatoid arthritis, are lacking for hemophilic arthropathy.
The pathophysiology of blood-induced joint damage involves a combination of synovium-mediated processes and direct cartilage degeneration. During natural clearing of blood components from the synovial cavity, iron accumulates within the synovial tissue, inducing inflammation, proliferation and angiogenesis [13] [14] [15] . This subsequently leads to cartilage degeneration via the production of proinflammatory cytokines and matrix-degrading enzymes. Besides this, synovial-independent direct harmful effects on cartilage result from erythrocyte-derived catalytic iron in combination with interleukin (IL)-1-induced enhancement of hydrogen peroxide production by chondrocytes. Thereby, hydroxyl radicals are produced in the vicinity of the cells, causing chondrocyte death [16] .
It has been demonstrated previously that IL-4 and IL-10 limit blood-induced cartilage damage in vitro [17, 18] and in vivo [19] . Because IL-4 and IL-10 use different signaling pathways [20] they are able to exert different, potentially additive, effects. It has been postulated that combined administration of these cytokines has synergistic effects as a result of complementary, yet partially overlapping, functionalities [21, 22] . However, despite their promising effects in preclinical studies, their clinical efficacy is limited. This is considered at least in part to be the result of limited bioavailability due to rapid clearance of these small cytokines.
Recently, we developed an IL4-10 fusion protein, retaining the biologic activity of both individual cytokines. This fusion protein has clear anti-inflammatory, immune regulatory, analgesic and chondroprotective effects in human in vitro models and animal in vivo models [23, 24] . In the present study we investigated whether the IL4-10 fusion protein protects against blood-induced joint damage in a human in vitro model of blood-induced cartilage damage, and joint damage upon hemarthrosis in a murine in vivo model of hemophilic arthropathy. Its efficacy was compared with the individual cytokines and their combination.
Materials and methods

Construction of the IL4-10 fusion protein
A fusion protein of human IL-4 and IL-10 was produced by transient transfection of HEK293 cells, co-transfected with alpha2,3-sialyltransferase 5 (SIAT9, homo sapiens) to optimize glycan-capping with sialic acid. This protein consists of human IL-4 at the N-terminus, a linker sequence, and human IL-10 at the C-terminus (Figure S1 ). IL4-10 fusion protein was purified by cation exchange chromatography, and stored in sterile phosphate buffered saline (PBS), pH 7.4, at À80°C (for further details see Eijkelkamp et al. [23] ). Murine IL4-10 fusion protein was made in a similar way to the human IL4-10 fusion protein, including co-transfection with alpha2,3-sialyltransferase 5 ( Figure S1 ). Purification was performed via cation exchange chromatography with additional size exclusion chromatography on a highperformance liquid chromatography (HPLC) system (Shimadzu, Kyoto, Japan). Fractions containing the fusion protein were pooled, sterile filtered, dialysed against PBS and stored at À80°C.
Experimental design in vitro study
Healthy human articular cartilage (obtained post-mortem from the humeral head; n = 8; mean age 69.8 AE 8.7 years; three men and five women) was exposed to 50% volume/ volume whole blood from healthy human donors (n = 8; mean age 28.0 AE 5.0 years; two men and six women) for 4 days to mimic a human joint bleed [25] . After 12 days of recovery (day 16), proteoglycan turnover was evaluated by determining proteoglycan synthesis rate, proteoglycan content and the release of proteoglycans into culture medium.
In the first set of experiments (n = 5), IL4-10 fusion protein was added during blood exposure at a concentration of 0.3 pg mL À1 to 100 ng mL À1 (two steps per log unit). To compare its efficacy with the individual components, in a second set of experiments addition of 10 ng mL À1 of the fusion protein was compared with addition of 10 ng mL À1 of IL-4 and/or IL-10 (both Sigma-Aldrich, St Louis, MO, USA) during blood exposure (n = 8).
To study the effect of the IL4-10 fusion protein and the individual cytokines IL-4 and IL-10 on the production of pro-inflammatory cytokines, separate whole blood cultures (50% v/v in culture medium) without cartilage were performed. Blood samples from six healthy donors (age 26.7 AE 1.6 years; two men and four women) were cultured for 4 days. The fusion protein, IL-4, IL-10 or a combination of both cytokines (all 10 ng mL À1 ) was added. After 4 days samples were collected, centrifuged at 1500 g for 10 min, and supernatants stored at À80°C. The concentrations of IL-1b and IL-6 were determined with commercially available ELISAs (both Invitrogen, Waltham, MA, USA) according to the manufacturer's instructions.
To test the hypothesis that the fusion protein acts on inhibiting the pro-inflammatory activity of monocytes/ macrophages, a separate set of experiments was performed. The effect of 10 ng mL À1 IL4-10 fusion protein on monocytes/macrophages stimulated by lysed red blood cells (RBCs) was compared with its effect on monocytes/ macrophages only (n = 6; age 31.3 AE 9.2 years; four men and two women). After 4 days of culture, IL-1b and IL-6 concentrations in the supernatants were measured.
Experimental design murine in vivo study FVIII-deficient mice (B6; 129S4-F8-tm1Kaz/J; 39 male and 41 female) at least 3 months of age were anesthetized with isofluran/O 2 and hair over both knee joints was removed. A joint bleed was induced in the right knee on days 0 and 14 with a 30-Gauge needle inserted through the infra-patellar ligament, as previously described [6, 26] .
Subsequently, 3 lL PBS containing 7 pmol murine IL4-10 fusion protein (n = 25), recombinant murine IL-4 and IL-10 (both 7 pmol; R&D systems, Minneapolis, MN, USA; n = 25) or PBS only (n = 30) was injected intraarticularly on days 0, 2, 14 and 16. Intra-articular injection was performed using a 33-Gauge needle, shown not to induce bleeding [27] . Sample size calculation using Cohen's effect size was based on demonstrating a difference in cartilage degeneration in the intervention groups compared with the PBS group. The left knee of each animal served as an unaffected control. Joint diameter was measured at days 0, 2, 14, 16 and 35 using a micrometer caliper. The visual bleeding score (VBS) was assessed daily according to Valentino et al. [28] . Animals were euthanized by cervical dislocation on day 35, the skin over the knee joints was removed and the greatest diameter across the joint from lateral to medial measured. Knee joints were isolated and joint damage was assessed histologically. Hematoxylin-eosin (H&E)-stained sections were used to score synovial inflammation according to the Valentino score [29] . For cartilage damage, Safranin-O Fast-Green (Saf-O)-stained sections were assessed according to the loss of Saf-O and scored using an adapted version of the Osteoarthritis Research Society International (modified OARSI) score specific for the mouse [27, 30, 31] . For specific details, we refer to the methods provided in Data S1.
Statistical analysis
Data analysis was performed using SPSS 21.0 (IBM, Chicago, IL, USA) software. Because data from the in vitro experiments were not normally distributed and this could not be achieved for all parameters by log-transformation, the Wilcoxon-signed rank test for related samples was performed to determine statistical significance between treatments and controls of cartilage or blood from the same donor sample.
For the in vivo experiments, continuous data were analyzed using the paired samples t-test and one-way ANOVA with Bonferroni correction. Ordinal data were analyzed using the Wilcoxon signed rank test and Pearson chisquared test. Longitudinal changes in joint diameter and VBS were tested using a general linear model for repeated measures.
Differences were considered to be statistically significant when P < 0.05.
Results
IL4-10 fusion protein dose-dependently protects cartilage against blood-induced damage in vitro
Exposure of human cartilage tissue to 50% v/v whole blood for 4 days strongly impacted proteoglycan turnover when compared with control cultures (proteoglycan synthesis, À74%, P = 0.043; glycosaminoglycan (GAG) release + 65%, P = 0.080; GAG content À16%, P = 0.043; Fig. 1 ). Addition of the IL4-10 fusion protein resulted in a dosedependent recovery of proteoglycan synthesis rate with a sigmoidal dose-response curve. The inhibition was statistically significantly different from a concentration of 0.1 ng mL À1 when compared with blood exposure only (all P = 0.043). Also GAG release was reversed by addition of the IL4-10 fusion protein, with a statistically significant improvement from 0.1 ng mL À1 (all P = 0.043, except for 1 ng mL À1 , P = 0.080). Moreover, GAG content improved upon fusion protein addition, being statistically significant at concentrations of 0.3 ng mL À1 and higher (all P = 0.043, except for 1 and 100 ng mL À1 , both P = 0.080).
IL4-10 fusion protein similarly effective to the combination of IL-4 and IL-10 in vitro
To investigate whether fusion of the individual cytokines affected its chondroprotective properties, addition of the IL4-10 fusion protein, IL-4, IL-10 and a combination of both cytokines (each 10 ng mL
À1
) was tested in the same assay. Blood exposure again severely impacted proteoglycan turnover (synthesis À76%, P = 0.012; release + 59%, P = 0.017; content À10%, P = 0.012; Fig. 2 ). Addition of IL-10 or IL-4 improved both the synthesis rate (P = 0.017 and P = 0.012, respectively) and GAG release (both P = 0.012), but did not result in a significant improvement of GAG content. The protective effect of IL-4 was stronger than that of IL-10 (P = 0.036 for synthesis; P = 0.012 for release).
Adding a combination of IL-4 and IL-10 (10 ng mL À1 each) also strongly improved proteoglycan turnover compared with blood exposure only, as did addition of 10 ng mL À1 fusion protein (all parameters P < 0.05).
There was no difference in the effects of the combination of IL-4 plus IL-10 vs. those of the IL4-10 fusion protein (P = 0.401 for synthesis; P = 0.611 for release; P = 0.484 for content).
IL4-10 fusion protein inhibits pro-inflammatory cytokine production
In whole blood cultures, the effect of the IL4-10 fusion protein on IL-1b and IL-6 production, being important mediators in blood-induced cartilage tissue damage, was investigated. In control culture media (containing 10% human serum), IL-1b was not detectable, whereas a very low concentration of IL-6 (68 pg mL À1 ) was measured. In 50% v/v blood cultures both cytokines were present (109 pg mL À1 IL-1b; 27 ng mL À1 IL-6; P = 0.043 and P = 0.028 compared with control cultures; Fig. 3A , B), and these levels were strongly reduced by addition of the IL4-10 fusion protein, the combination of IL-4 plus IL-10 or the cytokines separately (all P < 0.05). IL-10 alone was slightly less effective than the IL4-10 fusion protein, the combination of IL-4 and IL-10, or IL-4 alone in reducing IL-6 production (all P < 0.05), but for IL-1b production no difference was found. The IL4-10 fusion protein was as effective as the combination of IL-4 plus IL-10 (P = 0.180 for IL-1b and P = 0.173 for IL-6).
To investigate the hypothesis that the IL4-10 fusion protein acted on CD14 + monocytes/macrophages, the effect on IL-1b and IL-6 production in 4-day cultures of monocytes/macrophages alone or in combination with lysed RBCs was tested. Monocytes/macrophages stimulated with lysed RBCs produced significantly more IL-1b and IL-6 (323 pg mL À1 IL-1b and 3492 pg mL À1 IL-6) compared with medium only (11 pg mL À1 and 19 pg mL À1 , respectively; both P = 0.028), whereas the concentration of IL-1b and IL-6 in the supernatant of monocytes/macrophages only did not differ from medium (monocytes/macrophages produced 12 pg mL À1 IL-1b and 818 pg mL À1 IL-6; P = 0.917 and P = 0.116 compared with medium; Fig. 3C, D) . all P < 0.05 when compared with the same condition without fusion protein).
Effects of the IL4-10 fusion protein on joint bleeding in vivo
In hemophilic mice, a joint bleed was induced in the right knee joint twice with a 2-week interval, resulting in an overall animal survival of 55% (n = 17 in the PBS group, n = 11 in the mouse IL-4 plus IL-10, and n = 16 in the mouse IL4-10 fusion protein treated group; survival after bleeding did not significantly differ between treatment groups; P = 0.355). After the punctures, the VBS and joint diameter increased equally in all treatment groups, gradually decreasing over time (Fig. 4) . ) and cytokine production was measured in the supernatants. In a separate set of experiments, CD14 + monocytes/macrophages were cultured for 4 days (C&D; n = 6) in the absence or presence of lysed red blood cells (RBCs), 10 ng mL À1 of the IL4-10 FP was added and cytokine production was measured in the supernatants. Median and interquartile range (IQR) are depicted. # P < 0.05 compared with control values; *P < 0.05 compared with blood 50%.
In all groups, the diameter of the experimental paw at the end of the study was significantly increased compared with the control paw ( Table 1 ). The diameter of the control joint, the diameter of the intervention joint and the delta difference (experimental minus control joint) did not differ between treatment groups (P = 0.111, P = 0.617 and P = 0.314, respectively).
Synovial inflammation is not affected by intra-articular IL4-10 fusion protein in the murine joint bleeding model
The left untreated knee showed similar synovial changes in each treatment group ( Fig. 5C ; P = 0.395). Upon two sequential joint bleeds, a statistically significant increase in Valentino score was noted (P = 0.000 compared with control in the PBS group), and intra-articular treatment with IL-4 plus IL-10 or the IL4-10 fusion protein did not attenuate this (still P = 0.003 and P = 0.001 compared with control in IL-4 plus IL-10 and IL4-10 fusion protein treated groups, respectively). There was no difference between the treatment groups in total Valentino score (P = 0.339), nor in any of the subscales (data not shown).
Intra-articular IL4-10 fusion protein treatment attenuates blood-induced cartilage damage in vivo
Loss of Saf-O staining, representing cartilage damage, was seen in the experimental joints, significantly differing from the contralateral joints in the PBS and IL-4 plus IL-10 groups ( Fig. 5D ; P = 0.001 and P = 0.008, respectively). In contrast, there was no significant increase in the modified OARSI score in mice treated with IL4-10 fusion protein compared with the contralateral joint (P = 0.201), although still an increase was noted. Comparing the modified OARSI score between the different treatment groups showed no statistically significant difference (P = 0.401 for comparison of the contralateral control joints; P = 0.401 for experimental joints; P = 0.175 for delta). The amelioration of cartilage damage by the IL4-10 fusion protein was equally present in the femoral condyle and tibial plateau (data not shown).
Discussion
This study demonstrates the chondroprotective potential of an IL4-10 fusion protein in blood-induced joint damage. In a human in vitro model the fusion protein prevents blood-induced cartilage degeneration in a dosedependent manner up to complete normalization. This is at least in part the result of suppressing IL-1b and IL-6 production by monocytes/macrophages, especially when activated by hemoglobin-derived iron. Addition of the (combination of the) individual cytokines showed a similar effect on cartilage damage. This cartilage-protective effect was confirmed in an in vivo murine joint bleeding model. Intra-articular treatment with the fusion protein, in contrast to the individual components, resulted in attenuation of cartilage damage upon two successive joint bleeds. In vivo, synovial inflammation was not affected by PBS, phosphate buffered saline. Joint diameter (mm) was measured after removal of the skin and defined as the greatest diameter across the joint from lateral to medial, expressed as mean AE standard deviation (SD). *One-way repeated ANOVA for comparison between treatment groups. †Paired t-test for comparison of the control with the experimental joints.
injection of the individual components nor the combination. IL-4 and IL-10 are regulatory cytokines demonstrating impressive results in in vitro and in vivo models of (auto-) inflammatory driven joint diseases [22, 32, 33] . Nevertheless, in clinical trials the promising effects of these cytokines were not seen [34] [35] [36] , possibly, at least in part, because of suboptimal bioavailability of these small molecules. IL-4 and IL-10 have a molecular weight of 18-20 kDa, below the critical size for filtration in the kidney (50-60 kDa depending on charge). The half-life of human IL-10 is about 1.9 h after intravenous injection, and 2.7-4.5 h after subcutaneous administration in healthy volunteers [37] [38] [39] . With a half-life of only 19 min after intravenous injection, IL-4 is even more rapidly cleared, as it does not form dimers, whereas IL-10 does [40] . Because of its higher molecular weight of~70 kDa [23] , the IL4-10 fusion protein is predicted to have a longer half-life than IL-4 or IL-10. This was indeed observed in preliminary rat pharmacokinetic studies (C. Steen-Louws, unpublished observation from ongoing pharmacokinetic studies). Moreover, the fusion protein provides an option for combined administration of both activities in a single molecule [41] .
The versatile properties of IL-4 and IL-10 are also demonstrated for the IL4-10 fusion protein. It reduces pro-inflammatory cytokine production in whole blood assays [42] , in cultures of human osteoarthritic cartilage The difference between the experimental joint and contralateral control joint is depicted as median and interquartile range (IQR). P-values for these differences are given at the top of the graph. There are no statistical differences between treatment groups.
and in synovial tissue [24] . Cartilage matrix turnover of osteoarthritic explants is improved by the fusion protein, and the cartilage destructive properties of osteoarthritic synovial tissue are reduced. Furthermore, in vivo analgesic properties are demonstrated in mouse models of chronic inflammatory pain [23] and in a large animal model of osteoarthritis [43] . Upon joint bleeding, IL-4 and IL-10 can limit cartilage damage. They reduce inflammation via inhibition of the production of IL-1b and TNFa by inflamed synovial tissue [44] , and by synovial fluid monocytes/macrophages [17] . Hence, less chondrocyte activation and subsequent hydrogen peroxide production will occur, limiting chondrocyte apoptosis [16, 45] . Additionally, a direct chondroprotective effect is suggested as blood exposure induces upregulation of the IL-4 and IL-10 receptors on chondrocytes [17] . In vivo, a single injection of the individual cytokines diminishes cartilage degeneration upon a joint bleed in hemophilic mice [19] .
The current study for the first time investigates the efficacy of a novel IL4-10 fusion protein in blood-induced cartilage damage. In vitro, the chondroprotective activity of IL4-10 fusion protein was comparable to the combination of the separate cytokines IL-4 and IL-10. A potential synergistic effect of IL-4 and IL-10 could not be demonstrated, as there was a ceiling effect; IL-4 at the concentration used already exerted maximal effects on proteoglycan turnover parameters and suppression of pro-inflammatory cytokine production. The concentrations used in the blood(-cartilage) cultures were based on previous studies demonstrating an optimal effect at 10 ng mL À1 [17, 18] . Whole blood cultures were repeated with 10-and 100-fold lower concentrations, also showing full blockade of pro-inflammatory cytokine production by the fusion protein (data not shown). It cannot be ruled out that further lowering the concentrations of IL-4 and IL-10 may display synergistic effects in this system, as has been described previously in arthritis models [21] . The in vivo potential of the fusion protein was investigated in a well-established hemophilia mouse model [19, 46, 47] . A previous study by our group investigating the in vivo efficacy of IL-4 and IL-10 showed only mild cartilage degeneration, compared with clear synovitis upon a single joint bleed [19] . Therefore, in the current study two bleeds were induced to better represent the human situation in which recurrent joint bleeds over time lead to arthropathy [48] . The drawback of a repeated injury model without clotting factor administration is an increased mortality, as demonstrated by a survival of 35% after three injuries in a study by Narkbunnam et al. [46] . In our study, survival after two injuries was 55% without a difference between treatment groups. Treatment was administered intra-articularly twice after each bleed to ascertain adequate availability of the active compounds. Intra-articular delivery of active compounds such as factor IX and microRNA is shown to be feasible in hemophilic mice [49, 50] , and this could be an interesting concept for delivery of our fusion protein, especially when formulated in a slow-release system.
The fusion protein hardly affected synovial inflammation at day 35 measured with the Valentino score. To confirm absence of efficacy on synovitis, also the Krenn score (used in rheumatoid arthritis [51] ) and Goldenberg&Cohen score (degenerative joint diseases [52] ) were assessed. Neither showed an improvement upon treatment with the fusion protein or the individual cytokines (data not shown). A well-known side-effect of IL-4 is an increase in inflammation as it is a chemo-attractant for macrophages and fibroblasts [33] . High levels induce accumulation of tissue macrophages and erythrophagocytosis in mice [53] . This pro-inflammatory potential is also suggested in K/BxN mice, where IL-4 appeared crucial for full development of arthritis [54] . In combination with IL-10 a better balance between the Th1 and Th2 responses can be achieved [32] and therefore both cytokines were combined in the fusion protein. However, in our study neither the fusion protein nor the combination of IL-4 and IL-10 affected synovial inflammation at day 35 after the first joint bleed. This is in line with previous studies demonstrating that blocking inflammatory cytokines alone is insufficient to avoid blood-induced synovitis in hemophilia mice [46] . Removing blood-components from the synovial cavity obviously induces a vigorous trigger for synovial inflammation. Although limiting cartilage damage, no previous treatment investigated for joint bleeding in hemophilia mice could influence synovitis [19, 27, 31] , unless combined with clotting factor concentrate [46, 55] . This is potentially because of an ineffective treatment, although it might also be the result of the vigorously increased synovial response to bleeding in mice not receiving clotting factor concentrate.
In line with the in vitro results, intra-articular injection of the IL4-10 fusion protein ameliorated cartilage damage in vivo. Such a beneficial effect was not observed with the individual cytokines, in contrast to our previous in vivo findings [19] . This can presumably be attributed to the increased severity of the model of repeated, rather than a single, joint bleed (average change in modified OARSI score in the vehicle group in the previous study was <1 [19] , whereas in the current study this was > 2). Nevertheless, the IL4-10 fusion protein still alleviated cartilage damage in this repeated joint bleed model. It is likely that the better bioavailability as a result of its higher molecular weight, contributes to the increased efficacy of the fusion protein vs. the combination of the separate cytokines.
Exploring the therapeutic potential of the IL4-10 fusion protein as a disease-modifying therapy in blood-induced joint damage seems appealing, especially in combination with clotting factor replacement therapy. Besides the chondroprotective properties and suppression of proinflammatory cytokine production, as demonstrated in the current study, also analgesic properties are ascribed to the fusion protein [23, 24] . Joint pain has a significant impact on quality of life in hemophilia patients [56] . Whether this potential analgesic effect influenced mobility of the mice, needs further investigation. It is demonstrated that loading the joint after a bleed aggravates cartilage damage [57] , which might negatively affect the chondroprotective efficacy of the fusion protein, causing an underestimation of its effect. It would have been interesting to study pain and movements in the present study as well. However, no data are available on pain in this model, and at the start of this study the analgesic properties of the IL4-10 fusion protein were not yet known.
In conclusion, this study demonstrates for the first time that the IL4-10 fusion protein prevents blood-induced cartilage damage in a human cartilage tissue in vitro model and ameliorates cartilage degeneration upon repeated joint bleeds in hemophilic mice when injected intra-articularly. These data justify further investigation of the potency of the IL4-10 fusion protein in the treatment of blood-induced arthropathy.
